Focus Stocks
Sanofi-Aventis near Support
Published on Wednesday, 25 January 2012 08:44 Written by Danny Miller
New York, January 25th (TradersHuddle.com) - Shares of Sanofi-Aventis (NYSE:SNY) are trading very close to calculated support at $35.09 with current price action closing at just $36.29 places the stock price near levels where traders will start paying attention.
Sanofi-Aventis' current stock range is defined by current calculated support defined at $35.09 and by the resistance level at $37.44, which should be used by traders planning their trades. These support and resistance levels are based on an algorithm of peaks and troughs of the stock price action.
Traders wanting to establish a position should place close attention to Sanofi-Aventis' price action, and establish a position as close to support as possible, but only after buying materializes. Traders should understand that the resistance point at $37.44 might limit their upside, however if the stock breaks resistance, it could be a good point to add to the position.
Sanofi-Aventis (NYSE:SNY) is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.
Related Articles
- Europe: More Is Needed
- Is Sanofi-Aventis Resistance Ahead?
- Sanofi-Aventis Is Dipping Below Support
- New Ratings: NVS, SNY, CYS
- Sanofi-Aventis Is Close to its 200 Day Moving Average
- Trading Idea: Is Sanofi-Aventis close to Support?
- Reference Points for Sanofi-Aventis
- Genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Manufacturing Plant
- Sanofi iBGStar® Blood Glucose Monitoring System Now Available in the U.S.
- Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Related Partner Headlines
- Sanofi (SNY): Today's Featured Health Care Loser - TheStreet.com
- Sanofi Stock To Go Ex-dividend Monday (SNY) - TheStreet.com
- Sanofi Q1 Net Profit Jumps 50% - Benzinga
- Talon: Assessing Marqibo's FDA Odds - TheStreet.com
- Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice - Benzinga
- Sanofi (SNY): Today's Featured Health Care Loser - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Something's Not Right in the Video-Game Space - TheStreet.com -
Stock Futures Rise on Eurobond Talk - TheStreet.com -
You Can Let Your Guard Down: Ask Noah - TheStreet.com -
NYSE Is Winning the IPO Listing War - TheStreet.com -
Apple Strengthens Its Supply Chain - TheStreet.com -
Toyota Is Back as May Sales Continue Auto Industry Recovery - TheStreet.com -
One Emotional Market - TheStreet.com -
Mixed Signals Emerge From Bakken Shale - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus -
Continental Resources Names Kirk Kinnear as Vice President of Oil Marketing Logistics -
Charm Communications to Present at Three Conferences in June -
Senior Management at UVMF Prepares to Pitch Some Big Ideas to Facebook -
XPO Logistics to Participate in Investor Conferences -
IntercontinentalExchange Announces Record Brent Crude Option Volume -
Grand Reopening Weekend Set for Newly Remodeled Life Time Fitness Six Forks Center May 26-27 -
Unwired Planet Takes Flight With a Tribute to Our Inventors and Their Impact on the Mobile Internet









